EDSA — Edesa Biotech, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1540159 ·
Ontario, Canada
Last close
$4.01
Market Cap
$38.66M
52W High
$20.32
52W Low
$0.72
ADV30
73,453
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,412,181 | -5,407,611 | 12,721,195 | 10,332,520 | 3,910,041 |
| Mar 2026 | 0 | — | -4,230,766 | -4,218,332 | 12,384,738 | 10,003,683 | 2,187,921 |
| Dec 2025 | 0 | — | -2,238,958 | -2,247,669 | 14,710,442 | 12,051,748 | 756,163 |
| Sep 2025 | 0 | — | -2,223,098 | -2,228,358 | 13,530,518 | 10,792,172 | 1,078,536 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,525,717
Investing CF
—
Financing CF
$3,532,922
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.32
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-72,451,359
Inventory
—
Receivables
$216,468
ST Investments
—
EBIT TTM
$-10,413,284
Pretax Income TTM
$-10,443,023
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | -7,127,672 | -7,185,523 | 13,530,518 | 1,078,536 | 12,451,982 | -7,322,262 |
| Sep 2024 | 0 | -6,316,467 | -6,170,045 | 3,813,982 | 1,832,827 | 1,981,155 | -4,890,205 |
| Sep 2023 | 0 | -8,641,719 | -8,374,415 | 8,890,437 | 1,841,637 | 7,048,800 | -6,636,483 |
| Sep 2022 | 0 | -17,590,533 | -17,548,924 | 11,575,728 | 2,184,439 | 9,391,289 | -12,279,302 |
| Sep 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.93
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRVO | CervoMed Inc. | $38.40M | $2.54 | — |
| IMMP | IMMUTEP Ltd | $38.32M | $0.26 | — |
| MIRA | MIRA PHARMACEUTICALS, INC. | $37.82M | $0.90 | — |
| ATNM | Actinium Pharmaceuticals, Inc. | $37.73M | $1.20 | — |
| BCTX | BriaCell Therapeutics Corp. | $37.58M | $4.32 | — |
News headlines (Yahoo Finance, 1h cache)
EDSA: Recruitment in Phase 2 Vitiligo Study Set to Get Underway
2026-08-24 08:02 · Yahoo
Edesa Biotech Stock Sinks After Fresh Capital Raise
2026-08-20 10:20 · Yahoo
Edesa Biotech Announces Proposed Public Offering
2026-08-19 20:01 · Yahoo
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
2026-08-13 20:15 · Yahoo
EDSA: Positive Exploratory Data in Patients with AKI
2026-07-02 12:02 · Yahoo
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
2026-06-11 13:15 · Yahoo
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
2026-06-05 13:20 · Yahoo
EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial
2026-05-22 12:15 · Yahoo
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results
2026-05-14 20:30 · Yahoo
Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment
2026-04-20 14:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.